Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US. Ryoncil (remestemcel-L-rknd) has been granted approval by the FDA for ...

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better for treating some subgroups than others. Prasinezumab was originally ...

The Swedish pharma company Orexo and biotech firm Abera Bioscience announced today that they have joined forces to develop mucosal vaccines, including an influenza vaccine candidate. The collaboration ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to identify and validate new drug targets for neurodegenerative diseases. GSK and ...

Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases.

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity drugs Mounjaro and Zepbound.

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo delivery expertise to develop new genetic medicines. The launch of nChroma is ...

The company will start enrolling patients with Stargardt disease in the first half of 2025. The Spanish genetic medicines company SpliceBio announced today that the FDA has cleared its investigational ...